# Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer

> **NCT00905021** · PHASE1,PHASE2 · TERMINATED · sponsor: **Baylor Breast Care Center** · enrollment: 4 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Exemestane
- **DRUG:** Sutent

## Key facts

- **NCT ID:** NCT00905021
- **Lead sponsor:** Baylor Breast Care Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-03
- **Primary completion:** 2011-01
- **Final completion:** 2012-02
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Sponsor withdrew support
- **Last updated:** 2020-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00905021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00905021, "Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00905021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*